SCHEMBL4153749

SCHEMBL4153749

CCOc1cc(C)ncc1NC(=O)c1ccnc2[nH]c(-c3ccsc3)nc12

nearest known ligand 0.46

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 12/20 0.46
MET P08581 1/20 0.41
POLQ O75417 1/20 0.39
GSK3A P49840 3/20 0.37
TP53 P04637 2/20 0.36
KDM4E B2RXH2 1/20 0.36
LMNA P02545 1/20 0.36
PKM P14618 1/20 0.36
GAA P10253 1/20 0.36
CHEK2 O96017 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
WNT1 P04628 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4154179 0.89 GSK3B (0.58) GSK3BMETGSK3A
SCHEMBL4161481 0.86 GSK3B (0.61) GSK3BGSK3ATP53MEN1KMT2A
SCHEMBL4152519 0.84 GSK3B (0.51) GSK3BPOLQTP53LMNAGAA
SCHEMBL4152058 0.82 GSK3B (0.45) GSK3BGSK3ALMNAMEN1KMT2A
SCHEMBL4159232 0.80 GSK3B (0.59) GSK3BMETPOLQGSK3AWNT1
SCHEMBL13778056 0.80 GSK3B (0.52) GSK3BMETGSK3AWNT1
SCHEMBL4156879 0.79 GSK3B (0.46) GSK3BMETGSK3ACHEK2WNT1
SCHEMBL4152983 0.79 GSK3B (0.65) GSK3BGSK3A
SCHEMBL4161267 0.77 GSK3B (0.46) GSK3BMETPOLQGSK3AWNT1
SCHEMBL4148138 0.77 GSK3B (0.53) GSK3BMETGSK3AWNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US claimed
EP-1984370-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Crystalgenomics, Inc. (KR) 2008-10-29 EP claimed
WO-2007083978-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME CRYSTALGENOMICS, INC. (KR) 2007-07-26 WO claimed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same GSK3B, GSK3A, MAP3K3 GSK3B 1/4885MET 1418/4885POLQ 2428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.